

Form 51-102F3 Material Change Report

Item 1: Name and Address of Company

NeonMind Biosciences Inc. (the “Company”)
Suite 200 – 1238 Homer Street
Vancouver, BC V6B 2Y5

Item 2: Date of Material Change

January 6, 2021

Item 3: News Release

A news release was issued and disseminated on January 7, 2021 via www.baystreet.com and www.stockwatch.com and filed on SEDAR at www.sedar.com.

Item 4: Summary of Material Change

On January 7, 2021, the Company announced that Trevor Millar was appointed as its Chief Psychedelic Officer.

Item 5: Full Description of Material Change

Trevor Millar was appointed as the Chief Psychedelic Officer of the Company effective January 6, 2021.

Mr. Millar will assist the Company in the key areas of developing policy, establishing multi-party projects that use psychedelics to address community health needs such as addiction, assisting the Company in developing safe and effective protocols for psychedelic treatments for one or more human clinical trials to be submitted for approval to Health Canada, and working within the psychedelic industry to build alliances and partnerships and to identify potential acquisition targets for the Company.

Mr. Millar will continue his work as a director of the Multidisciplinary Association of Psychedelic Studies (MAPS) Canada and as a director of the Canadian Psychedelic Association and will devote 80% of his professional time to his duties as Chief Psychedelic Officer of the Company.

Item 6: Reliance on subsection 7.1(2) of National Instrument 51-102

Not applicable.

Item 7: Omitted Information

None.

Item 8: Executive Officer

Penny White
CEO and President
Telephone: (833) 514-2677

Item 9: Date of Report

January 16, 2021